ESMO Breast Cancer Congress
Regardless of HER2 Expression, Responses Are Showcased With Sacituzumab Govitecan in TNBC
May 26, 2022
Article
Sacituzumab govitecan-hziy significantly improved progression-free survival in patients with HER2-low expressing TNBC and HER2-negative disease.
Entrectinib Generates Favorable Outcomes in NTRK Fusion+ Breast Cancer
May 14, 2022
Article
Entrectinib elicited encouraging responses in patients with breast cancer that harbors NTRK fusions, according to updates from the phase 2 STARTRK-2 trial.
Trastuzumab Deruxtecan Continues to Elicit Responses in HER2+ Breast Cancer With Active Brain Metastases
May 09, 2022
Article
Patients with HER2-positive breast cancer who also have brain metastases experienced clinical benefit with fam-trastuzumab deruxtecan-nxki in the phase 2 TUEXEDO-trial.
Advertisement
Advertisement